SG11201807003UA - Smc combination therapy for the treatment of cancer - Google Patents
Smc combination therapy for the treatment of cancerInfo
- Publication number
- SG11201807003UA SG11201807003UA SG11201807003UA SG11201807003UA SG11201807003UA SG 11201807003U A SG11201807003U A SG 11201807003UA SG 11201807003U A SG11201807003U A SG 11201807003UA SG 11201807003U A SG11201807003U A SG 11201807003UA SG 11201807003U A SG11201807003U A SG 11201807003UA
- Authority
- SG
- Singapore
- Prior art keywords
- ontario
- international
- ottawa
- rule
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000005775 apoptotic pathway Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000008088 immune pathway Effects 0.000 abstract 1
- 244000309459 oncolytic virus Species 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662299288P | 2016-02-24 | 2016-02-24 | |
PCT/CA2017/050237 WO2017143449A1 (en) | 2016-02-24 | 2017-02-23 | Smc combination therapy for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807003UA true SG11201807003UA (en) | 2018-09-27 |
Family
ID=59684762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807003UA SG11201807003UA (en) | 2016-02-24 | 2017-02-23 | Smc combination therapy for the treatment of cancer |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210322545A1 (ko) |
EP (1) | EP3419643A4 (ko) |
JP (1) | JP2019506438A (ko) |
KR (1) | KR20180120208A (ko) |
CN (1) | CN108883187A (ko) |
AU (2) | AU2017223233A1 (ko) |
BR (1) | BR112018017195A2 (ko) |
CA (1) | CA3014504A1 (ko) |
CL (1) | CL2018002408A1 (ko) |
EA (1) | EA201891904A1 (ko) |
IL (2) | IL291844B2 (ko) |
MX (1) | MX2018010202A (ko) |
PH (1) | PH12018501751A1 (ko) |
SG (1) | SG11201807003UA (ko) |
TN (1) | TN2018000294A1 (ko) |
WO (1) | WO2017143449A1 (ko) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
US20200199624A1 (en) * | 2017-05-19 | 2020-06-25 | Georgia State University Research Foundation, Inc. | Recombinant oncolytic virus |
JP7422070B2 (ja) | 2017-10-19 | 2024-01-25 | デバイオファーム インターナショナル エス.エー. | 癌の治療のための配合剤 |
WO2019122941A1 (en) | 2017-12-21 | 2019-06-27 | Debiopharm International Sa | Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule |
MX2020008333A (es) * | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
TWI816603B (zh) | 2018-04-23 | 2023-09-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
WO2020024932A1 (en) | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule |
CN113453678A (zh) | 2018-11-26 | 2021-09-28 | 德彪药业国际股份公司 | Hiv感染的联合治疗 |
US20220096436A1 (en) | 2019-01-17 | 2022-03-31 | Debiopharm International S.A. | Combination product for the treatment of cancer |
TW202043466A (zh) | 2019-01-25 | 2020-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
EP4034102A1 (en) | 2019-09-25 | 2022-08-03 | Debiopharm International SA | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
US20240091284A1 (en) * | 2019-10-10 | 2024-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus comprising immunomodulatory transgenes and uses thereof |
US20230029259A1 (en) * | 2019-12-02 | 2023-01-26 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of iap inhibitors and parp or mek inhibitors or other chemotherapeutic agents |
MX2022015261A (es) * | 2020-06-03 | 2023-03-14 | Boehringer Ingelheim Int | Rhabdovirus recombinante que codifica una proteina de fusion fc de dominio extracelular cd80. |
JP2024502615A (ja) * | 2021-01-11 | 2024-01-22 | セネカ セラピューティクス、インク. | チェックポイント阻害剤抵抗性のがんを治療するためのセネカバレーウイルス併用療法 |
WO2022179490A1 (en) * | 2021-02-23 | 2022-09-01 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical compositions and preparation methods thereof |
JPWO2022250070A1 (ko) | 2021-05-28 | 2022-12-01 | ||
KR20240038991A (ko) * | 2021-07-19 | 2024-03-26 | 리제너론 파마슈티칼스 인코포레이티드 | 암을 치료하기 위한 체크포인트 저해제 및 종양용해 바이러스의 조합 |
CN114010666B (zh) * | 2021-10-22 | 2024-05-07 | 上海交通大学 | 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用 |
CN116819085A (zh) * | 2023-06-02 | 2023-09-29 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 生长抑素受体2在用于制备肝细胞癌预后评估的试剂盒中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2109460B1 (en) * | 2007-01-11 | 2016-05-18 | Novo Nordisk A/S | Anti-kir antibodies, formulations, and uses thereof |
US8283372B2 (en) * | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
WO2015069785A1 (en) * | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
AU2014369446C1 (en) * | 2013-12-20 | 2020-03-12 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
WO2015109391A1 (en) * | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
EP3389712B1 (en) * | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
-
2017
- 2017-02-23 WO PCT/CA2017/050237 patent/WO2017143449A1/en active Application Filing
- 2017-02-23 MX MX2018010202A patent/MX2018010202A/es unknown
- 2017-02-23 SG SG11201807003UA patent/SG11201807003UA/en unknown
- 2017-02-23 US US15/999,804 patent/US20210322545A1/en not_active Abandoned
- 2017-02-23 CN CN201780021033.6A patent/CN108883187A/zh active Pending
- 2017-02-23 KR KR1020187027746A patent/KR20180120208A/ko not_active Application Discontinuation
- 2017-02-23 AU AU2017223233A patent/AU2017223233A1/en not_active Abandoned
- 2017-02-23 EP EP17755686.7A patent/EP3419643A4/en not_active Withdrawn
- 2017-02-23 EA EA201891904A patent/EA201891904A1/ru unknown
- 2017-02-23 TN TNP/2018/000294A patent/TN2018000294A1/en unknown
- 2017-02-23 IL IL291844A patent/IL291844B2/en unknown
- 2017-02-23 CA CA3014504A patent/CA3014504A1/en active Pending
- 2017-02-23 BR BR112018017195A patent/BR112018017195A2/pt unknown
- 2017-02-23 JP JP2018544934A patent/JP2019506438A/ja active Pending
-
2018
- 2018-08-15 IL IL261171A patent/IL261171A/en unknown
- 2018-08-17 PH PH12018501751A patent/PH12018501751A1/en unknown
- 2018-08-23 CL CL2018002408A patent/CL2018002408A1/es unknown
-
2022
- 2022-03-30 AU AU2022202181A patent/AU2022202181A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EA201891904A1 (ru) | 2019-04-30 |
MX2018010202A (es) | 2019-06-06 |
PH12018501751A1 (en) | 2019-05-15 |
CA3014504A1 (en) | 2017-08-31 |
IL291844B2 (en) | 2023-10-01 |
JP2019506438A (ja) | 2019-03-07 |
KR20180120208A (ko) | 2018-11-05 |
IL291844B1 (en) | 2023-06-01 |
EP3419643A1 (en) | 2019-01-02 |
WO2017143449A1 (en) | 2017-08-31 |
TN2018000294A1 (en) | 2020-01-16 |
EP3419643A4 (en) | 2020-04-01 |
IL291844A (en) | 2022-06-01 |
US20210322545A1 (en) | 2021-10-21 |
CL2018002408A1 (es) | 2019-01-18 |
BR112018017195A2 (pt) | 2019-01-02 |
CN108883187A (zh) | 2018-11-23 |
AU2017223233A1 (en) | 2018-08-30 |
IL261171A (en) | 2018-10-31 |
AU2022202181A1 (en) | 2022-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807003UA (en) | Smc combination therapy for the treatment of cancer | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201901550WA (en) | Method and apparatus for data processing | |
SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201903604PA (en) | Iot security service | |
SG11201809437TA (en) | Intracellular delivery of biomolecules to induce tolerance | |
SG11201808457PA (en) | Icos ligand variant immunomodulatory proteins and uses thereof | |
SG11201810627UA (en) | Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases | |
SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
SG11201804770QA (en) | Method and arrangement for recovery of salt | |
SG11201805118XA (en) | Solid fluorescence standard | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
SG11201805771XA (en) | Systems and methods for preparation of platelets | |
SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof | |
SG11201809534UA (en) | Methods of treating autoimmune disease using allogeneic t cells | |
SG11201901457TA (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same |